Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Amortization of Deferred Charges: 2016-2023

Historic Amortization of Deferred Charges for Whitehawk Therapeutics (WHWK) over the last 4 years, with Dec 2023 value amounting to -$3.1 million.

  • Whitehawk Therapeutics' Amortization of Deferred Charges rose 54.41% to -$486,000 in Q4 2023 from the same period last year, while for Dec 2023 it was -$2.3 million, marking a year-over-year change of. This contributed to the annual value of -$3.1 million for FY2023, which is 158.11% down from last year.
  • According to the latest figures from FY2023, Whitehawk Therapeutics' Amortization of Deferred Charges is -$3.1 million, which was down 158.11% from -$1.2 million recorded in FY2022.
  • Over the past 5 years, Whitehawk Therapeutics' Amortization of Deferred Charges peaked at -$1.2 million during FY2022, and registered a low of -$3.1 million during FY2023.
  • In the last 2 years, Whitehawk Therapeutics' Amortization of Deferred Charges had a median value of -$2.2 million in 2022 and averaged -$2.2 million.
  • Data for Whitehawk Therapeutics' Amortization of Deferred Charges shows a maximum YoY crashed of 158.11% (in 2023) over the last 5 years.
  • Yearly analysis of 2 years shows Whitehawk Therapeutics' Amortization of Deferred Charges stood at -$1.2 million in 2022, then tumbled by 158.11% to -$3.1 million in 2023.